Arrowhead Pharmaceuticals’ (ARWR) “Buy” Rating Reiterated at Chardan Capital

Arrowhead Pharmaceuticals (NASDAQ:ARWR)‘s stock had its “buy” rating reaffirmed by equities research analysts at Chardan Capital in a report released on Tuesday,Benzinga reports. They presently have a $90.00 price objective on the biotechnology company’s stock. Chardan Capital’s price target would indicate a potential upside of 11.80% from the stock’s current price.

A number of other equities analysts have also recently weighed in on ARWR. Sanford C. Bernstein upped their price target on Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a report on Wednesday, May 13th. JPMorgan Chase & Co. initiated coverage on Arrowhead Pharmaceuticals in a report on Friday, May 1st. They issued an “overweight” rating and a $88.00 price objective on the stock. Weiss Ratings cut Arrowhead Pharmaceuticals from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Wednesday, May 20th. Royal Bank Of Canada upped their target price on Arrowhead Pharmaceuticals from $80.00 to $87.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Finally, Leerink Partners increased their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a “market perform” rating in a research report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $87.27.

Arrowhead Pharmaceuticals Trading Up 2.0%

Shares of Arrowhead Pharmaceuticals stock opened at $80.50 on Tuesday. The firm has a 50-day simple moving average of $75.85 and a two-hundred day simple moving average of $68.42. The company has a market cap of $11.34 billion, a P/E ratio of -37.44 and a beta of 1.28. Arrowhead Pharmaceuticals has a fifty-two week low of $14.30 and a fifty-two week high of $84.55. The company has a debt-to-equity ratio of 1.41, a quick ratio of 6.23 and a current ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative net margin of 48.38% and a negative return on equity of 55.09%. The business had revenue of $73.74 million for the quarter, compared to analyst estimates of $73.84 million. During the same period in the prior year, the company posted $2.75 EPS. The company’s revenue for the quarter was down 86.4% on a year-over-year basis. As a group, equities analysts predict that Arrowhead Pharmaceuticals will post -3 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider James C. Hamilton sold 10,000 shares of the stock in a transaction dated Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total value of $750,000.00. Following the completion of the sale, the insider directly owned 226,958 shares in the company, valued at $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Hongbo Lu sold 2,970 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $76.88, for a total transaction of $228,333.60. Following the completion of the transaction, the director directly owned 52,012 shares in the company, valued at approximately $3,998,682.56. This represents a 5.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,065 shares of company stock valued at $1,912,662 in the last 90 days. 3.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ARWR. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $25,000. Optiver Holding B.V. increased its holdings in shares of Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 186 shares during the last quarter. iSAM Funds UK Ltd purchased a new position in Arrowhead Pharmaceuticals during the third quarter worth approximately $29,000. First Horizon Corp purchased a new position in Arrowhead Pharmaceuticals during the fourth quarter worth approximately $32,000. Finally, WPG Advisers LLC boosted its stake in Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock worth $36,000 after buying an additional 431 shares during the last quarter. 62.61% of the stock is owned by hedge funds and other institutional investors.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.